百濟神州(06160.HK)2023年總收入增長74%達25億美元 期待在新的一年裏取得變革性突破
格隆匯2月26日丨百濟神州(06160.HK)公吿，公司全球業務持續快速增長，營收再創新高，2023年第四季度總收入達6.34億美元，同比增長67%；全年總收入達25億美元，同比增長74%。
百悦澤(澤布替尼)在血液學領域進一步鞏固領導地位，2023年第四季度全球銷售額達4.13億美元，同比增長135%；全年全球銷售額達13億美元，同比增長129%。
2023年第四季度，公司產品收入達6.305億美元，同比增長86%；全年產品收入達22億美元，同比增長75%。
2023年第四季度和全年，毛利佔全球產品收入分別為83.2%和82.7%，上年同期為78.3%和77.2%。季度及全年的毛利率同比均取得增長，主要是由於與公司的其他產品組合以及毛利率較低的授權許可產品相比，百悦澤全球產品銷售額佔比較高，且百悦澤和百澤安的單位成本較低。
“回顧2023年第四季度和全年，百濟神州取得了長足的進展，朝着成為具有影響力的新一代腫瘤創新公司的目標不斷邁進。隨着百悦澤在全球尤其是美國和歐洲市場持續取得成功，我們進一步鞏固了在血液學領域的領導地位”。百濟神州聯合創始人、董事長兼首席執行官歐雷強(John V. Oyler)先生表示，“憑藉在研發和生產方面的成本優勢，我們構建了業內規模最大、最令人振奮的腫瘤研發管線之一。我們期待百濟神州在新的一年裏取得變革性的突破，通過在全球不同地區推動收入的顯著增長，持續實現卓越運營”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
